(NASDAQ: SUPN) Supernus Pharmaceuticals's forecast annual revenue growth rate of 13.72% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.25%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.92%.
Supernus Pharmaceuticals's revenue in 2025 is $665,125,000.On average, 1 Wall Street analysts forecast SUPN's revenue for 2025 to be $39,138,454,693, with the lowest SUPN revenue forecast at $39,138,454,693, and the highest SUPN revenue forecast at $39,138,454,693. On average, 1 Wall Street analysts forecast SUPN's revenue for 2026 to be $47,316,714,578, with the lowest SUPN revenue forecast at $47,316,714,578, and the highest SUPN revenue forecast at $47,316,714,578.
In 2027, SUPN is forecast to generate $54,727,333,888 in revenue, with the lowest revenue forecast at $54,727,333,888 and the highest revenue forecast at $54,727,333,888.